Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches.

Ratti M, Lampis A, Hahne JC, Passalacqua R, Valeri N.

Cell Mol Life Sci. 2018 Sep 1. doi: 10.1007/s00018-018-2906-9. [Epub ahead of print] Review.

PMID:
30173350
2.

Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial.

Khan KH, Cunningham D, Werner B, Vlachogiannis G, Spiteri I, Heide T, Mateos JF, Vatsiou A, Lampis A, Darvish Damavandi M, Lote H, Huntingford IS, Hedayat S, Chau I, Tunariu N, Mentrasti G, Trevisani F, Rao S, Anandappa G, Watkins D, Starling N, Thomas J, Peckitt C, Khan N, Rugge M, Begum R, Hezelova B, Bryant A, Jones T, Proszek P, Fassan M, Hahne JC, Hubank M, Braconi C, Sottoriva A, Valeri N.

Cancer Discov. 2018 Aug 30. doi: 10.1158/2159-8290.CD-17-0891. [Epub ahead of print]

PMID:
30166348
3.

Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma.

Mensah AA, Cascione L, Gaudio E, Tarantelli C, Bomben R, Bernasconi E, Zito D, Lampis A, Hahne JC, Rinaldi A, Stathis A, Zucca E, Kwee I, Gattei V, Valeri N, Riveiro ME, Bertoni F.

Haematologica. 2018 Aug 3. pii: haematol.2018.191684. doi: 10.3324/haematol.2018.191684. [Epub ahead of print]

4.

MicroRNAs as Mediators of Resistance Mechanisms to Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumours.

Ghidini M, Hahne JC, Frizziero M, Tomasello G, Trevisani F, Lampis A, Passalacqua R, Valeri N.

Target Oncol. 2018 Aug;13(4):423-436. doi: 10.1007/s11523-018-0580-3.

PMID:
30006826
5.

Non-Coding RNAs and Resistance to Anticancer Drugs in Gastrointestinal Tumors.

Hahne JC, Valeri N.

Front Oncol. 2018 Jun 18;8:226. doi: 10.3389/fonc.2018.00226. eCollection 2018. Review.

6.

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.

Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernández-Mateos J, Khan K, Lampis A, Eason K, Huntingford I, Burke R, Rata M, Koh DM, Tunariu N, Collins D, Hulkki-Wilson S, Ragulan C, Spiteri I, Moorcraft SY, Chau I, Rao S, Watkins D, Fotiadis N, Bali M, Darvish-Damavandi M, Lote H, Eltahir Z, Smyth EC, Begum R, Clarke PA, Hahne JC, Dowsett M, de Bono J, Workman P, Sadanandam A, Fassan M, Sansom OJ, Eccles S, Starling N, Braconi C, Sottoriva A, Robinson SP, Cunningham D, Valeri N.

Science. 2018 Feb 23;359(6378):920-926. doi: 10.1126/science.aao2774.

7.

KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer.

Sclafani F, Chau I, Cunningham D, Hahne JC, Vlachogiannis G, Eltahir Z, Lampis A, Braconi C, Kalaitzaki E, De Castro DG, Wotherspoon A, Capdevila J, Glimelius B, Tarazona N, Begum R, Lote H, Hulkki Wilson S, Mentrasti G, Brown G, Tait D, Oates J, Valeri N.

Sci Rep. 2018 Jan 23;8(1):1445. doi: 10.1038/s41598-018-19212-5.

8.

First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction: final results and biomarker analysis from an Italian oncology group for clinical research (GOIRC) phase II study.

Tomasello G, Valeri N, Ghidini M, Smyth EC, Liguigli W, Toppo L, Mattioli R, Curti A, Hahne JC, Negri FM, Panni S, Ratti M, Lazzarelli S, Gerevini F, Colombi C, Panni A, Rovatti M, Treccani L, Martinotti M, Passalacqua R.

Oncotarget. 2017 Dec 4;8(67):111795-111806. doi: 10.18632/oncotarget.22909. eCollection 2017 Dec 19.

9.

MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma.

Lampis A, Carotenuto P, Vlachogiannis G, Cascione L, Hedayat S, Burke R, Clarke P, Bosma E, Simbolo M, Scarpa A, Yu S, Cole R, Smyth E, Mateos JF, Begum R, Hezelova B, Eltahir Z, Wotherspoon A, Fotiadis N, Bali MA, Nepal C, Khan K, Stubbs M, Hahne JC, Gasparini P, Guzzardo V, Croce CM, Eccles S, Fassan M, Cunningham D, Andersen JB, Workman P, Valeri N, Braconi C.

Gastroenterology. 2018 Mar;154(4):1066-1079.e5. doi: 10.1053/j.gastro.2017.10.043. Epub 2017 Nov 4.

10.

Characterisation of the immune-related transcriptome in resected biliary tract cancers.

Ghidini M, Cascione L, Carotenuto P, Lampis A, Trevisani F, Previdi MC, Hahne JC, Said-Huntingford I, Raj M, Zerbi A, Mescoli C, Cillo U, Rugge M, Roncalli M, Torzilli G, Rimassa L, Santoro A, Valeri N, Fassan M, Braconi C.

Eur J Cancer. 2017 Nov;86:158-165. doi: 10.1016/j.ejca.2017.09.005. Epub 2017 Oct 6.

11.

Clinical development of mTor inhibitors for renal cancer.

Ghidini M, Petrelli F, Ghidini A, Tomasello G, Hahne JC, Passalacqua R, Barni S.

Expert Opin Investig Drugs. 2017 Nov;26(11):1229-1237. doi: 10.1080/13543784.2017.1384813. Epub 2017 Oct 3. Review.

PMID:
28952411
12.

Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study.

Khan K, Rata M, Cunningham D, Koh DM, Tunariu N, Hahne JC, Vlachogiannis G, Hedayat S, Marchetti S, Lampis A, Damavandi MD, Lote H, Rana I, Williams A, Eccles SA, Fontana E, Collins D, Eltahir Z, Rao S, Watkins D, Starling N, Thomas J, Kalaitzaki E, Fotiadis N, Begum R, Bali M, Rugge M, Temple E, Fassan M, Chau I, Braconi C, Valeri N.

Gut. 2018 Aug;67(8):1484-1492. doi: 10.1136/gutjnl-2017-314178. Epub 2017 Aug 8.

13.

Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer.

Lote H, Spiteri I, Ermini L, Vatsiou A, Roy A, McDonald A, Maka N, Balsitis M, Bose N, Simbolo M, Mafficini A, Lampis A, Hahne JC, Trevisani F, Eltahir Z, Mentrasti G, Findlay C, Kalkman EAJ, Punta M, Werner B, Lise S, Aktipis A, Maley C, Greaves M, Braconi C, White J, Fassan M, Scarpa A, Sottoriva A, Valeri N.

Ann Oncol. 2017 Jun 1;28(6):1243-1249. doi: 10.1093/annonc/mdx074.

14.

Clinical outcome and molecular characterization of brain metastases from esophageal and gastric cancer: a systematic review.

Ghidini M, Petrelli F, Hahne JC, De Giorgi A, Toppo L, Pizzo C, Ratti M, Barni S, Passalacqua R, Tomasello G.

Med Oncol. 2017 Apr;34(4):62. doi: 10.1007/s12032-017-0919-0. Epub 2017 Mar 18. Review.

PMID:
28315230
15.

MicroRNA 193b-3p as a predictive biomarker of chronic kidney disease in patients undergoing radical nephrectomy for renal cell carcinoma.

Trevisani F, Ghidini M, Larcher A, Lampis A, Lote H, Manunta P, Alibrandi MT, Zagato L, Citterio L, Dell'Antonio G, Carenzi C, Capasso G, Rugge M, Rigotti P, Bertini R, Cascione L, Briganti A, Salonia A, Benigni F, Braconi C, Fassan M, Hahne JC, Montorsi F, Valeri N.

Br J Cancer. 2016 Nov 22;115(11):1343-1350. doi: 10.1038/bjc.2016.329. Epub 2016 Nov 1.

16.

Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers.

Carotenuto P, Fassan M, Pandolfo R, Lampis A, Vicentini C, Cascione L, Paulus-Hock V, Boulter L, Guest R, Quagliata L, Hahne JC, Ridgway R, Jamieson T, Athineos D, Veronese A, Visone R, Murgia C, Ferrari G, Guzzardo V, Evans TRJ, MacLeod M, Feng GJ, Dale T, Negrini M, Forbes SJ, Terracciano L, Scarpa A, Patel T, Valeri N, Workman P, Sansom O, Braconi C.

Gut. 2017 Jul;66(7):1268-1277. doi: 10.1136/gutjnl-2016-312278. Epub 2016 Sep 12.

17.

New developments in the treatment of chemotherapy-induced neutropenia: focus on balugrastim.

Ghidini M, Hahne JC, Trevisani F, Panni S, Ratti M, Toppo L, Tomasello G.

Ther Clin Risk Manag. 2016 Jun 24;12:1009-15. doi: 10.2147/TCRM.S80732. eCollection 2016. Review.

18.

Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients.

Sclafani F, Chau I, Cunningham D, Lampis A, Hahne JC, Ghidini M, Lote H, Zito D, Tabernero J, Glimelius B, Cervantes A, Begum R, De Castro DG, Wilson SH, Peckitt C, Eltahir Z, Wotherspoon A, Tait D, Brown G, Oates J, Braconi C, Valeri N.

Carcinogenesis. 2016 Sep;37(9):852-7. doi: 10.1093/carcin/bgw073. Epub 2016 Jul 5.

19.

Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial.

Smyth EC, Fassan M, Cunningham D, Allum WH, Okines AF, Lampis A, Hahne JC, Rugge M, Peckitt C, Nankivell M, Langley R, Ghidini M, Braconi C, Wotherspoon A, Grabsch HI, Valeri N.

J Clin Oncol. 2016 Aug 10;34(23):2721-7. doi: 10.1200/JCO.2015.65.7692. Epub 2016 Jun 13.

20.

Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial.

Sclafani F, Chau I, Cunningham D, Peckitt C, Lampis A, Hahne JC, Braconi C, Tabernero J, Glimelius B, Cervantes A, Begum R, Gonzalez De Castro D, Hulkki Wilson S, Eltahir Z, Wotherspoon A, Tait D, Brown G, Oates J, Valeri N.

Ann Oncol. 2015 Sep;26(9):1936-41. doi: 10.1093/annonc/mdv285. Epub 2015 Jul 10.

21.

Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS-126 in models of ovarian cancer.

Hahne JC, Kurz A, Meyer SR, Dietl J, Engel JB, Honig A.

Arch Gynecol Obstet. 2015 Jan;291(1):131-41. doi: 10.1007/s00404-014-3389-z. Epub 2014 Aug 13.

PMID:
25115278
22.

The effect of Cordyceps extract and a mixture of Ganoderma lucidum/Agaricus Blazi Murill extract on human endometrial cancer cell lines in vitro.

Hahne JC, Meyer SR, Dietl J, Honig A.

Int J Oncol. 2014 Jul;45(1):373-82. doi: 10.3892/ijo.2014.2414. Epub 2014 May 5.

PMID:
24805296
23.

Studies on the role of osteopontin-1 in endometrial cancer cell lines.

Hahne JC, Meyer SR, Kranke P, Dietl J, Guckenberger M, Polat B, Hönig A.

Strahlenther Onkol. 2013 Dec;189(12):1040-8. doi: 10.1007/s00066-013-0434-y. Epub 2013 Oct 16.

PMID:
24126938
24.

Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1.

Engel JB, Honig A, Kapp M, Hahne JC, Meyer SR, Dietl J, Segerer SE.

Arch Gynecol Obstet. 2014 Jan;289(1):141-7. doi: 10.1007/s00404-013-2922-9. Epub 2013 Jul 5.

PMID:
23828443
25.

Immune escape of AKT overexpressing ovarian cancer cells.

Hahne JC, Meyer SR, Gambaryan S, Walter U, Dietl J, Engel JB, Honig A.

Int J Oncol. 2013 May;42(5):1630-5. doi: 10.3892/ijo.2013.1846. Epub 2013 Mar 4.

PMID:
23467686
26.

Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS 126 in models of triple-negative breast cancer.

Hahne JC, Schmidt H, Meyer SR, Engel JB, Dietl J, Honig A.

J Cancer Res Clin Oncol. 2013 Jun;139(6):905-14. doi: 10.1007/s00432-013-1399-z. Epub 2013 Feb 26.

PMID:
23440492
27.

Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitro.

Hahne JC, Honig A, Meyer SR, Gambaryan S, Walter U, Wischhusen J, Häussler SF, Segerer SE, Fujita N, Dietl J, Engel JB.

Oncol Rep. 2012 Dec;28(6):2023-8. doi: 10.3892/or.2012.2041. Epub 2012 Sep 18.

PMID:
22992944
28.

Peptidomimetic GnRH antagonist AEZS-115 inhibits the growth of ovarian and endometrial cancer cells.

Engel JB, Hahne JC, Häusler SF, Meyer S, Segerer SE, Diessner J, Dietl J, Honig A.

Anticancer Res. 2012 May;32(5):2063-8.

PMID:
22593489
29.

PI3K inhibitor D-116883 is effective in in vitro models of ovarian cancer.

Honig A, Hahne JC, Meyer S, Kranke P, Häusler S, Diessner J, Dietl J, Engel JB.

Anticancer Res. 2012 May;32(5):2035-41.

PMID:
22593485
30.

Effects of lobaplatin as a single agent and in combination with TRAIL on the growth of triple-negative p53-mutated breast cancers in vitro.

Engel JB, Martens T, Hahne JC, Häusler SF, Krockenberger M, Segerer S, Djakovic A, Meyer S, Dietl J, Wischhusen J, Honig A.

Anticancer Drugs. 2012 Apr;23(4):426-36. doi: 10.1097/CAD.0b013e32834fb8ce.

PMID:
22314264
31.

Evaluation of effects caused by differentially spliced Ets-1 transcripts in fibroblasts.

Hahne JC, Fuchs T, Florin A, Edwards D, Pourtier A, Soncin F, Wernert N.

Int J Oncol. 2011 Nov;39(5):1073-82. doi: 10.3892/ijo.2011.1152. Epub 2011 Aug 9.

PMID:
21833469
32.

Identification of ETS-1 target genes in human fibroblasts.

Hahne JC, Okuducu AF, Fuchs T, Florin A, Wernert N.

Int J Oncol. 2011 Jun;38(6):1645-52. doi: 10.3892/ijo.2011.981. Epub 2011 Mar 21.

PMID:
21424123
33.

Regulation of protein tyrosine kinases in tumour cells by the transcription factor Ets-1.

Hahne JC, Kummer S, Heukamp LC, Fuchs T, Gun M, Langer B, Von Ruecker A, Wernert N.

Int J Oncol. 2009 Nov;35(5):989-96.

PMID:
19787252
34.

Dominant-negative inhibition of Ets 1 suppresses tumor growth, invasion and migration in rat C6 glioma cells and reveals differentially expressed Ets 1 target genes.

Sahin A, Vercamer C, Kaminski A, Fuchs T, Florin A, Hahne JC, Mattot V, Pourtier-Manzanedo A, Pietsch T, Fafeur V, Wernert N.

Int J Oncol. 2009 Feb;34(2):377-89.

PMID:
19148472
35.

Outcome of outpatient neurology consultations: physician's evaluations compared to patients' perceptions.

Narayanaswami P, Hahne JC.

J Neurol Sci. 2009 Jan 15;276(1-2):175-8. doi: 10.1016/j.jns.2008.09.036. Epub 2008 Nov 20.

PMID:
19026430
36.

The transcription factor ETS-1: its role in tumour development and strategies for its inhibition.

Hahne JC, Okuducu AF, Sahin A, Fafeur V, Kiriakidis S, Wernert N.

Mini Rev Med Chem. 2008 Oct;8(11):1095-105. Review.

PMID:
18855726
37.

The potential of proteasome inhibitors in cancer therapy.

Sterz J, von Metzler I, Hahne JC, Lamottke B, Rademacher J, Heider U, Terpos E, Sezer O.

Expert Opin Investig Drugs. 2008 Jun;17(6):879-95. doi: 10.1517/13543784.17.6.879 . Review.

PMID:
18491989
38.

Tumor-stroma interactions of metastatic prostate cancer cell lines: analyses using microarrays.

Wernert N, Kaminski A, Haddouti el-M, Hahne JC.

Methods Mol Biol. 2007;382:223-37.

PMID:
18220234
39.

Influence of preoperative core biopsies on uPA/PAI-1 expression in breast cancer tissue.

Haas S, Park TW, Hahne JC, Fischer HP.

Virchows Arch. 2008 Mar;452(3):277-83. doi: 10.1007/s00428-007-0563-8.

PMID:
18196271
40.

The Ets-1 transcription factor is involved in pterygial angiogenesis.

Naib-Majani W, Breipohl W, Shazli EE, Theuerkauf I, Pleyer U, Hahne JC, Wernert N.

Anat Histol Embryol. 2007 Apr;36(2):107-10.

PMID:
17371382
41.

Tumour-stroma interactions between metastatic prostate cancer cells and fibroblasts.

Kaminski A, Hahne JC, Haddouti el-M, Florin A, Wellmann A, Wernert N.

Int J Mol Med. 2006 Nov;18(5):941-50.

PMID:
17016625
42.

Immunohistochemical quantification of lymph vessels, VEGF-C and VEGF receptor 3 in human sarcomas.

Friedrichs N, Hahne JC, Pepper MS, Rommerscheidt-Fuss U, Stelzner F, Buettner R, Wernert N.

Histopathology. 2006 Jul;49(1):87-8. No abstract available.

PMID:
16842251
43.

Expression pattern of matrix metalloproteinase and TIMP genes in fibroblasts derived from Ets-1 knock-out mice compared to wild-type mouse fibroblasts.

Hahne JC, Fuchs T, El Mustapha H, Okuducu AF, Bories JC, Wernert N.

Int J Mol Med. 2006 Jul;18(1):153-9.

PMID:
16786167
44.

Cellular retinoic acid-binding protein 2 is down-regulated in prostate cancer.

Okuducu AF, Janzen V, Ko Y, Hahne JC, Lu H, Ma ZL, Albers P, Sahin A, Wellmann A, Scheinert P, Wernert N.

Int J Oncol. 2005 Nov;27(5):1273-82.

PMID:
16211222
45.

Ets-1 expression promotes epithelial cell transformation by inducing migration, invasion and anchorage-independent growth.

Hahne JC, Okuducu AF, Kaminski A, Florin A, Soncin F, Wernert N.

Oncogene. 2005 Aug 11;24(34):5384-8.

PMID:
15940256
46.

Novel tempeh (fermented soyabean) isoflavones inhibit in vivo angiogenesis in the chicken chorioallantoic membrane assay.

Kiriakidis S, Högemeier O, Starcke S, Dombrowski F, Hahne JC, Pepper M, Jha HC, Wernert N.

Br J Nutr. 2005 Mar;93(3):317-23.

PMID:
15877870
47.

Inactivation of Ets 1 transcription factor by a specific decoy strategy reduces rat C6 glioma cell proliferation and mmp-9 expression.

Sahin A, Velten M, Pietsch T, Knuefermann P, Okuducu AF, Hahne JC, Wernert N.

Int J Mol Med. 2005 May;15(5):771-6.

PMID:
15806297
48.

Laser-assisted microdissection, techniques and applications in pathology (review).

Okuducu AF, Hahne JC, Von Deimling A, Wernert N.

Int J Mol Med. 2005 May;15(5):763-9. Review.

PMID:
15806296
49.

The Ets-1 transcription factor is involved in the development and invasion of malignant melanoma.

Rothhammer T, Hahne JC, Florin A, Poser I, Soncin F, Wernert N, Bosserhoff AK.

Cell Mol Life Sci. 2004 Jan;61(1):118-28.

PMID:
14704859
50.

Influence of histochemical stains on quantitative gene expression analysis after laser-assisted microdissection.

Okuducu AF, Janzen V, Hahne JC, Ko Y, Wernert N.

Int J Mol Med. 2003 Apr;11(4):449-53.

PMID:
12632096

Supplemental Content

Loading ...
Support Center